Profile of Gene Alterations in the MAPK Signaling Pathway, DNA/RNA Repair, and Cell Cycle Control and Regulation in Plasma Cell Neoplasms

Plasma cell neoplasms (PN) are a group of diseases, the main representatives of which are multiple myeloma (MM) and its asymptomatic predecessor, monoclonal gammopathy of undetermined significance (MGUS). PN are accompanied by various genetic abnormalities that arise at different stages of the disease. The most common of these include alterations in the cell cycle genes of the MAPK signaling pathway and DNA/RNA repair. This study presents the prevalence of KRAS, NRAS, and BRAF gene mutations and ATM and DIS3 gene polymorphisms in patients with newly diagnosed MM and MGUS.

1. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma: an IMWG Research Project / S. Z. Usmani [et al.] // Blood Cancer Journal. – 2018. – Vol. 8, No. 12. – P. 123.

2. Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group / M. K. A. Samur [et al.] // Journal of Clinical Oncology. – 2020 – Vol. 38, No. 27. – P. 3107–3118.

3. Asymptomatic multiple myeloma: background of progression, evolution, and prognosis / A. Seckinger [et al.] // Blood. – 2016. – Vol. 128, No. 22. – P. e235.

4. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression / M. Bustoros [et al.] // Journal of Clinical Oncology. – 2020. – Vol. 38, No. 21. – P. 2380–2389.

5. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma / S. V. Rajkumar [et al.] // The Lancet Oncology. – 2014. – Vol. 15, No. 12. – P. e538–e548.

6. Rajkumar, S. V. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management / S. V. Rajkumar // American Journal of Hematology. – 2018. – Vol. 93, No. 8. – P. 1091–1110.

7. Genomic profiling for clinical decision making in lymphoid neoplasms / L. De Leval [et al.] // Blood. – 2022. – Vol. 140, No. 21. – P. 2193–2227.

8. Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis / N. Li [et al.] // Cancer Medicine. – 2023. – Vol. 12, No. 13. – P. 14293–14304.

9. A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias / M. Lionetti [et al.] // Oncotarget. – 2015. – Vol. 6, No. 28. – P. 26129–26145.

10. BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma / E. M. Boyle [et al.] // Clinical Cancer Research. – 2020. – Vol. 26, No. 10. – P. 2422–2432.

11. DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome / K. Todoerti [et al.] // Haematologica. – 2021. – Vol. 107, No. 4. – P. 921–932.